More Than a CDMO

The End-to-End Support of Your Portfolio

lab safety


Partner with us for cell line and strain development, manufacturability assessments, cell banking and toxicology material generation. Let us guide your path to IND/IMPD submission.

doctor reassuring her senior patient

Clinical Phase I, II

Partner with us to develop your initial clinical process for cGMP drug substance and drug product manufacturing.

doctor asking senior patient health questions

Clinical Phase III

Partner with us to optimize, scale and characterize your process to meet anticipated therapeutic demands.

Family bonding time on the couch


Partner with us for process validation and process performance qualification. Leverage our CMC and regulatory services for your BLA/MAA submission and experience our reliability.

Setting New Standards in
Advanced Therapies and Biologic Advancements


Advanced Therapies

Unlock the future of healthcare with Advanced Therapies – a groundbreaking frontier in medical innovation.

cell rendering


Dive into the world of Biologics, harnessing the power of nature for revolutionary medical solutions.

Building exterior
coins icon

Billion USD Invested

in recent years


In the News

Business Update

Fujifilm reception desk in UK office
April 16, 2024 – FUJIFILM Diosynth Biotechnologies today announced the decision to globally restructure its Small Scale Business Unit, that may…
Investment to create an additional 680 highly-skilled local jobs by 2031; Adding large-scale production capacity to robust global network through state-of-the-art manufacturing hubs in the United States and Europe
HILLERØD, Denmark, March 25, 2024 – FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, advanced…
HOLLY SPRINGS, N.C. – March 11, 2024 – FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO)…